Analysis Tools|
Allele Symbol Allele Name Allele ID |
Spata13tm1Taki targeted mutation 1, Tetsu Akiyama MGI:5816603 |
||||||||||||||||||||||||
| Summary |
5 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice are viable, fertile and overtly normal with no detectable alterations in lung, spleen and liver histology
• intestinal structure, differentiation and physiology appear unaffected
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice are viable, fertile and overtly normal with no detectable alterations in lung, spleen and liver histology
• intestinal structure, differentiation and physiology appear unaffected
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice develop only a few small adenomas (polyps) by 4 months of age
|
|
• mice show loss of the wild-type Apc allele in the small adenomas formed
• Rac1 and Cdc42 signaling appears to be reduced
|
|
• the density of microvessels within adenomas is significantly lower than that in ApcMin heterozygotes
• however, tumor-associated macrophages are recruited to adenomas and release vascular endothelial growth factor normally
|
|
• mice develop only a few small adenomas (polyps) by 4 months of age
|
|
• the density of microvessels within adenomas is significantly lower than that in ApcMin heterozygotes
• however, tumor-associated macrophages are recruited to adenomas and release vascular endothelial growth factor normally
|
|
• treatment of mice with zoledronic acid (a specific inhibitor of MMP9) for 6 weeks fails to result in further suppression of adenoma formation, unlike in ApcMin heterozygotes
|
|
• mice develop only a few small adenomas (polyps) by 4 months of age
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice survive significantly longer than ApcMin heterozygotes
|
|
• at 4 months of age, mice show an even greater reduction in the total number of intestinal adenomas (polyps) per mouse than mice that are homozygous for Arhgef4tm1Taki and heterozygous for ApcMin
|
|
• at 4 months of age, mice show an even greater reduction in the size of intestinal adenomas (polyps) than mice that are homozygous for Arhgef4tm1Taki and heterozygous for ApcMin
|
|
• at 4 months of age, mice show an even greater reduction in the total number of intestinal adenomas (polyps) per mouse than mice that are homozygous for Arhgef4tm1Taki and heterozygous for ApcMin
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• at 4 months of age, mice show an intermediate reduction in the total number of intestinal adenomas (polyps) per mouse relative to mice that are homozygous for Spata13tm1Taki and heterozygous for ApcMin
|
|
• at 4 months of age, mice show an intermediate reduction in the size of intestinal adenomas (polyps) relative to mice that are homozygous for Spata13tm1Taki and heterozygous for ApcMin
|
|
• at 4 months of age, mice show an intermediate reduction in the total number of intestinal adenomas (polyps) per mouse relative to mice that are homozygous for Spata13tm1Taki and heterozygous for ApcMin
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 11/12/2024 MGI 6.24 |
|
|
|
||
